Brainstorm Cell Therapeutics (BCLI)
(Delayed Data from NSDQ)
$0.42 USD
+0.02 (5.00%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.42 0.00 (0.00%) 6:22 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BCLI 0.42 +0.02(5.00%)
Will BCLI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BCLI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCLI
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
BCLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BCLI
BrainStorm Cell Therapeutics announces pricing of $4M registered direct offering
BrainStorm to sell 11.11M shares at 36c in registered direct offering
BrainStorm reached alignment with FDA on Phase 3b clinical trial for NurOwn
Brainstorm Cell Therapeutics Appoints New EVP and COO
BrainStorm appoints Haro Hartounian as COO